Eleva leverages a moss-based production platform to manufacture biologics such as antibodies, replacement enzymes and fusion toxins. The company has developed drug candidates into clinical phases. Eleva secured up to €60m in funding from Zukunftsfonds Heilbronn. The proceeds are intended to advance its drug candidate CPV-101 to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. The financing announcement coincided with the appointment of Dr. Ralf Smit as Chief Business Officer; he previously advised Eleva and brings over 25 years of business development and commercialization experience with Roche and BioStrat.

Total raised

$74M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2021